Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxaliplatin + Irinotecan for metastatic colorectal cancer with high TS expression
2008-000217-30Phase 2Completed
- Sponsor
- Azienda Ospedaliera Universitaria Senese
- Start
- Feb 2008
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin and irinotecan in metastatic colon cancer (mCRC) and rectal cancer, sponsored by Azienda Ospedaliera Universitaria Senese. Primary endpoint: Objective therapeutic response. Started Feb 2008; status: completed.
02
Drugs
oxaliplatinirinotecan
03
Conditions
metastatic colon cancer (mCRC)rectal cancer
Beyond the preview
Go deeper on 2008-000217-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000217-30.